The dipeptide monoester prodrugs of floxuridine and gemcitabine - feasibility of orally administrable nucleoside analogs by Tsume, Yasuhiro et al.
 Pharmaceuticals 2014, 7, 169-191; doi:10.3390/ph7020169 
 
pharmaceuticals 
ISSN 1424-8247 
www.mdpi.com/journal/pharmaceuticals 
Article 
The Dipeptide Monoester Prodrugs of Floxuridine and 
Gemcitabine—Feasibility of Orally Administrable  
Nucleoside Analogs 
Yasuhiro Tsume 1, Blanca Borras Bermejo 2 and Gordon L. Amidon 1,* 
1 Department of Pharmaceutical Science, University of Michigan, Ann Arbor, MI 48109, USA 
2 Facultat De Medicina, Universitat de Lleida, Lleida, Catalunya 21007, Spain 
* Author to whom correspondence should be addressed; E-Mail: glamidon@umich.edu;  
Tel.: +734-764-2440; Fax: +734-763-6423. 
Received: 26 November 2013; in revised form: 15 January 2014 / Accepted: 22 January 2014 /  
Published: 27 January 2014  
 
Abstract: Dipeptide monoester prodrugs of floxuridine and gemcitabine were synthesized. 
Their chemical stability in buffers, enzymatic stability in cell homogenates, permeability in 
mouse intestinal membrane along with drug concentration in mouse plasma, and  
anti-proliferative activity in cancer cells were determined and compared to their parent drugs. 
Floxuridine prodrug was more enzymatically stable than floxuridine and the degradation 
from prodrug to parent drug works as the rate-limiting step. On the other hand, gemcitabine 
prodrug was less enzymatically stable than gemcitabine. Those dipeptide monoester prodrugs 
exhibited 2.4- to 48.7-fold higher uptake than their parent drugs in Caco-2, Panc-1, and 
AsPC-1 cells. Floxuridine and gemcitabine prodrugs showed superior permeability in mouse 
jejunum to their parent drugs and exhibited the higher drug concentration in plasma after in situ 
mouse perfusion. Cell proliferation assays in ductal pancreatic cancer cells, AsPC-1 and 
Panc-1, indicated that dipeptide prodrugs of floxuridine and gemcitabine were more potent 
than their parent drugs. The enhanced potency of nucleoside analogs was attributed to their 
improved membrane permeability. The prodrug forms of 5′-L-phenylalanyl-L-tyrosyl-
floxuridine and 5′-L-phenylalanyl-L-tyrosyl-gemcitabine appeared in mouse plasma after the 
permeation of intestinal membrane and the first-pass effect, suggesting their potential for 
the development of oral dosage form for anti-cancer agents. 
Keywords: gemcitabine prodrug; floxuridine prodrug; mouse in situ perfusion;  
pancreatic tumor cells; dipeptide 
 
OPEN ACCESS
Pharmaceuticals 2014, 7 170 
 
 
1. Introduction 
The anti-cancer agents 2′,2′-difluoro-2′-deoxyuridine (gemcitabine, Gemzar®) and 5-fluoro-2′-
deoxyuridine (floxuridine, FdUR), two nucleoside analogs, have been used to treat pancreatic, non-
small-cell lung, and colon cancers as the first-line therapy [1–4]. The adverse effects associated with 
those chemotherapeutics are still unresolved and the minimization of side-effects and the maximization 
of therapeutic efficacy for chemotherapeutic agents have been investigated. The modification of 
physicochemical properties has been examined to improve the therapeutic index. One of those 
strategies is a prodrug strategy. In this strategy, the focus on anti-viral and anti-cancer drugs has been 
developing their orally available dosage forms. Oral bioavailability and metabolic disposition of anti-viral 
drugs and anti-cancer drugs has been improved by designing for the transporter-targeted-delivery [4–13]. 
Amino acid monoester and dipeptide monoester prodrugs have been synthesized, characterized, and 
their potential to improve the oral bioavailability examined as a part of the development for oral drug 
delivery [7,11–18]. Reportedly, amino acid monoester prodrugs as well as dipeptide monoester prodrugs 
are substrates for intake transporters such as PEPT1, PEPT2, and ATB0,+, and the carrier-mediated 
mechanism with those transporters improves their oral bioavailability [19–24]. PEPT1 has broad 
substrate specificity and is expressed in the GI tract [25,26]. This transporter can transport dipeptides, 
tripeptides, amino acid monoester prodrugs and β-lactam antibiotics [11,27–33]. Yang and coworkers 
demonstrated that the importance of PEPT1 transporter for the oral absorption of valacyclovir in 
PEPT1 knockout mice [34]. The delivery of amino acid monoester and dipeptide monoester prodrugs 
might be enhanced in pancreatic ductal cancer cells, Panc-1 and AsPC-1s, due to the overexpression of 
oligopeptide transporters [11,12,35]. Moreover, dipeptide prodrugs might have more potential for the 
development of oral anti-cancer drugs because of their superior affinity to the PEPT1 transporter [9,11,21]. 
The anti-cancer nucleoside analogs such as 5-fluorouracil (5-FU), floxuridine, and gemcitabine 
have been investigated and their mechanistic action is well understood [36–39]. The main 
administration for anti-cancer nucleoside analogs to treat cancer is an intravenous route due to low and 
erratic oral bioavailability and stability issues [40,41]. Moreover, those analogs are converted to 
pyrimidine structure by metabolic enzymes such as thymidine phosphorylase in many tissues [11,41,42]. 
Thus, higher doses of those anti-cancer agents are required to assure clinical efficacy and have greater 
potential for toxicity. The improved chemical and enzymatic stabilities of anti-cancer drugs might lead 
to the reduction of adverse effect by lowering doses. Additionally, the prodrug strategy has been 
adopted to target the disease and tissue specific enzymes to minimize its adverse effects and/or to 
maximize its therapeutic effects [43–46]. 
In this report, L-phenylalanyl-L-tyrosine was adopted as a dipeptide promoiety for the anti-cancer 
prodrugs to assess the feasibility of orally administrative nucleoside analogs, floxuridine and 
gemcitabine, because of its potential for enzyme-specific prodrug activation [47]. As the part of 
developing orally administrative cancer agents, we describe the stability and permeability of dipeptide 
monoester prodrugs of gemcitabine and floxuridine, as well as their anti-proliferation activity in 
pancreatic cancer cells, AsPC-1 and Panc-1 cells. Uptake studies were conducted with Caco-2, Panc-1, 
and AsPC-1 cells with both the presence and the absence of 10 mM Gly-Pro and permeability studies 
were also performed with in situ mouse jejunal perfusion to determine the effective permeability (Peff). 
Furthermore, the feasibility of developing orally administrable chemotherapeutic agents was assessed 
Pharmaceuticals 2014, 7 171 
 
 
by measuring the drug concentration and drug species in plasma after the perfusion study. The 
chemical and enzymatic stabilities of dipeptide prodrugs of floxuridine and gemcitabine along with 
their parent drugs were also evaluated at physiological pH and in Caco-2, Panc-1, and AsPC-1 cell 
homogenates. The successful development of oral administrative anti-cancer drugs would improve the 
quality of life and drastically reduce the insurance costs for cancer patients [48]. 
2. Experimental Section 
2.1. Materials 
Gemcitabine was extracted from the lyophilized powder (Gemzar®) supplied by Eli Lilly 
Pharmaceuticals (Indianapolis, IN, USA). Floxuridine was obtained from Lancaster (Windham, NH, 
USA). The tert-butyloxycarbonyl (Boc)-protected dipeptide, Boc-L-phenylalanyl-L-tyrosine, was obtained 
from Chem-Impex (Wood Dale, IL, USA). High-performance liquid chromatography (HPLC) grade 
acetonitrile was obtained from Fisher Scientific (St. Louis, MO, USA). N,N-dicyclohexylcarbodiimide 
(DCC), N,N-dimethylaminopyridine (DMAP), trifluoroacetic acid (TFA), and all other reagents and 
solvents were purchased from Aldrich Chemical Co. (Milwaukee, WI, USA). Cell culture reagents 
were obtained from Invitrogen (Carlsbad, CA, USA) and cell culture supplies were obtained from Corning 
(Corning, NY, USA) and Falcon (Lincoln Park, NJ, USA). All chemicals were either analytical or 
HPLC grade. 
2.2. The Synthesis of Gemcitabine Prodrug and Floxuridine Prodrug 
The synthesis and characterization of 5′-monoamino acid ester prodrugs of gemcitabine and 
floxuridine and 5′-dipeptide ester prodrugs of floxuridine have been reported previously [7,11,13]. 
Briefly, Boc-protected dipeptide, Boc-L-phenylalanyl-L-tyrosine, (1.1 mmol), DCC (1.1 mmol), and 
DMAP (0.1 mmol) were allowed to react with gemcitabine or floxuridine (1 mmol) in 7 mL of dry 
DMF for 24 h. The reaction progress was monitored by thin layer chromatography (TLC) (ethyl 
acetate). The reaction mixture was filtered and dichloromethane (DCM) was removed under vacuum at 
40 °C. The residue was extracted with ethyl acetate (30 mL) and washed with water (2 × 20 mL), and 
saturated NaCl (20 mL). The organic layer was dried over MgSO4 and concentrated under vacuum. 
The reaction yielded a mixture of 3′-monoester, 5′-monoester, and 3′,5′-diester gemcitabine prodrugs 
and floxuridine prodrugs. The three spots observed on TLC were separated and purified using column 
chromatography (dichloromethane (DCM)/methanol, 20:1). Fractions from each spot were 
concentrated under vacuum separately. The Boc group was cleaved by treating the residues with 5 mL 
TFA/DCM (1:1). After 4 h, the solvent was removed and the residues were reconstituted with water 
and lyophilized. The TFA salts of dipeptide prodrugs of gemcitabine and floxuridine were obtained as 
white fluffy solids. The yields of 5′-dipeptide monoester gemcitabine prodrug and 5′-dipeptide 
monoester floxuridine prodrug were ~30% and ~35%, respectively. HPLC was used to evaluate the 
prodrug purity. Prodrugs were between 92%–99% pure. These prodrugs were easily separated from 
parent drug by HPLC. Electrospray ionization mass spectra (ESI-MS) were obtained on a Micromass 
LCT ESI-MS. The observed molecular weights of all prodrugs were found to be consistent with that 
required by their structure. The structural identity of the prodrugs was then confirmed using proton 
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nuclear magnetic resonance (1H-NMR) spectra obtained on a 300 MHz Bruker DPX-300 NMR 
spectrometer. The structural identity of 5′-L-phenylalanyl-L-tyrosyl-floxuridine has been reported 
previously [11]. 
5′-L-Phenylalanyl-L-tyrosyl-gemcitabine. Yield, 30%; percent purity: 92%; 1H-NMR (DMSO-d6) δ, 
11.40 (m, 1H), 9.27 (m, 2H), 8.95 (m, 1H), 8.36–8.06 (m, 4H), 7.48–6.97 (m, 7H), 6.79–6.56 (m, 2H), 
6.17 (m, 1H), 4.74–4.60 (m, 2H), 4.45 (m, 1H), 4.11 (m, 2H), 3.91–3.56 (m, 2H), 3.28–2.78 (m, 3H), 
2.01–1.97 (m, 2H); ESI-MS 574.4 (M+H)+. 
2.3. Cell Culture 
AsPC-1 cells (passages 30–40) from American Type Culture Collection (Rockville, MD, USA) 
were routinely maintained in RPMI-1640 containing 10% fetal bovine serum. Caco-2 cells (passages 
33–38) and Panc-1 (passages 20–35) from American Type Culture Collection) were routinely 
maintained in DMEM containing 10% fetal bovine serum. Cells were grown at 37 °C at 5% CO2 and 
90% relative humidity in antibiotic-free media to avoid the possible transport interference by antibiotics. 
2.4. Hydrolysis Studies 
2.4.1. Enzymatic Stability 
Confluent Caco-2, Panc-1, and AsPC-1cells were rinsed twice with phosphate buffered saline 
(PBS). The cells were lysed with phosphate buffer (pH 7.4) by ultrasonication (Micro ultrasonic cell 
disrupter Model KT40, Kontes, Vineland, NJ, USA), and pelleted by centrifugation for 5 min at 1,000 × g. 
Protein amount was quantified with the Bio-Rad (Hercules, CA, USA) DC Protein Assay using bovine 
serum albumin as a standard. The amount of protein was adjusted to 500 µg/mL and hydrolysis 
reactions were carried out in 96-well plates (Corning). Caco-2, Panc-1, and AsPC-1 cell suspensions 
(250 µL) were placed in triplicate wells, the reactions were started with the addition of substrate, and 
cells were incubated at 37 °C for 120 min. At the desired time point, sample aliquots (35 µL) were 
removed and added to acetonitrile (ACN, 150 µL) with 0.1% TFA. The mixtures were filtered with a 
0.45 µm filters at 1,000 × g for 10 min at 4 °C. The filtrate was then analyzed via reverse-phase HPLC. 
2.4.2. Chemical Stability 
The nonenzymatic hydrolysis of the prodrugs was determined as described above, except that each 
well contained pH 7.4 phosphate buffers (10 mmol/L) instead of cell homogenate. 
2.5. Uptake Studies 
Caco-2, Panc-1, and AsPC-1 cells were grown on a 6-well plate for 18, 6, and 6 days, respectively. 
Wells were rinsed with MES (pH 6.0) buffer twice. Fresh MES buffer was reapplied to each well and 
incubated at 37 °C for 15 min. Each drug was individually tested from freshly prepared solutions in 
MES buffer (0.1 mM, total 0.3 mL) with the presence and the absence of 10 mM glycyl-proline (Gly-Pro). 
The solution was placed in each well and incubated at 37 °C for 60 min. Drug solution was removed 
and 3 mL of ice-cold PBS was immediately placed in each well. Each well was rinsed with 3 mL of  
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cold-PBS twice and 0.5 mL of methanol/H2O (1:1) containing 0.1% TFA was placed in each well. The 
cell suspension was collected and transferred to a new tube. Those tubes were spun at 1,000 × g at 4 °C 
for 5 min. The supernatant was mixed with equal amount of water with either 0.1% formic acid or 
0.1% ammonium hydroxide for LC-MS analysis. The cell pullets were used to determine protein amount 
with the Bio-Rad DC Protein Assay using bovine serum albumin as a standard. 
2.6. Solution for Single-Pass Intestinal Perfusion 
The perfusion buffer (pH6.0) consisted of 145 mM NaCl, 0.5 mM MgCl2, 1 NaH2PO4, 1 mM CaCl2, 
3 mM KCl, 5 mM glucose, and 5 mM MES. The pH of the buffer was adjusted to pH6.0.  
This perfusion buffer also contained phenol-red (14 µM) as a non-absorbable marker for water  
flux measurements. 
2.7. Single-Pass Intestinal Perfusion Studies in Mice 
All animal experiments were conducted using protocols approved by the University of Michigan 
Committee of Use and Care of Animals (UCUCA). Female BALB/c mice (Charles River, IN, USA) 
weighing 20–25 g were used for all perfusion studies. Prior to each experiment, mice were fasted 
overnight with free access to water. 
The procedure for the in situ single-pass intestinal perfusion is previously reported [49]. Briefly, 
mice were anesthetized with an i.m. injection of ketamine-xylazine mixture (ketamine: 80–120 mg/kg, 
xylazine: 5–10 mg/kg) and placed on a heated pad maintained at 37 °C. The abdomen was opened by a 
midline incision and a jejunal segment (approximately 10 cm) was carefully exposed to cannulate both 
ends with flexible PVC tubing (2.06 mm i.d., Fisher Scientific Inc., Pittsburgh, PA, USA).  
All solutions were incubated in a 37 °C water-bath. The isolated segment was rinsed with blank 
perfusion buffer to clean out any residual debris. 
At the start of the study, the test compound (100 µM) in perfusion buffer (pH 6.0) including phenol 
red was perfused through the intestinal segment (Watson-Marlow Pump 323S, Watson-Marlow Bredel 
Inc., Wilimington, MA, USA), at the flow rate of 0.1 mL/min. The perfusion buffer was perfused for 
30 min to assure steady-state and samples were taken in every 10 min for 90 min. At the end of 
perfusion, blood samples were collected by cardiac puncture. Blood samples with heparin were 
centrifuged at 1,000 × g for 10 min at 4 °C to collect plasma samples for LC-MS analysis. Following 
the termination of the experiment, the length of each perfused intestinal segment was measured. 
2.8. Cell Proliferation Assays 
Cell proliferation studies were conducted with Panc-1 and AsPC-1 cells. The cells were seeded into 
96-well plates at 80,000 cells per well and allowed to attach/grow for 48 h before drug solutions were 
added. The culture medium (DMEM +10% fetal bovine serum or RPMI-1640 +10% fetal bovine 
serum) was removed and the cells were gently washed once with sterile pH 6.0 uptake buffer. 
Floxuridine, 5′-L-phenylalanyl-L-tyrosyl-floxuridine, gemcitabine and 5′-L-phenylalanyl-L-tyrosyl-
gemcitabine were 2-fold serially diluted in pH 6.0 uptake buffer from 5 to 0.078 mmol/L. Buffer alone 
was used as a 100% viability control. The wash buffer was removed and 30 µL drug solution per well 
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was added and incubated at 37 °C for 2 h in the cell incubator. After this time, the drug solutions were 
removed and the cells were again gently washed twice with sterile uptake buffer. The culture medium 
was then added to each well after washing. The cells were allowed to recover for 24 h before 
evaluating cell viability via 2,3-bis[2-methoxy-4-nitro-5-sulfophenyl]-2H-tetrazolium-5-carboxanilide 
inner salt (XTT) assays. A mixture (30 µL) containing XTT (1 mg/mL) in sterile RPMI-1640  
without phenol red and phenazine methosulfate (N-methyldibenzopyrazine methyl sulfate in sterile 
PBS, 0.383 mg/mL) reagents were added to the cells and incubated at 37 °C for 1 h, after which the 
absorbance at 450 nm was read. The concentrations required to inhibit cell growth by 50% (GI50) were 
calculated using GraphPad Prism version 3.0 by nonlinear data fitting. 
2.9. Data Analysis 
The net water flux in the mouse perfusion studies was determined using phenol red (14 µM), a  
non-absorbed and non-metabolized marker. The measured Cout/Cin ratio of test compound was 
corrected for water flux according to the following equation: 
 
where Cin phenol red and Cout phenol red are equal to the concentration of phenol red in the inlet and the outlet 
samples, respectively. The effective permeability (Peff; cm/s) through the mouse intestinal wall in the 
single-pass intestinal perfusion studies was determined according to the following equation: 
 
where Q is the perfusion buffer flow rate (0.1 mL/min), C′out/C′in is the ratio of the outlet/inlet 
concentration of test compound that is adjusted for water transport, R is the radius of the intestinal 
segment (set to 0.1 cm), and L is the length of the perfused intestinal segment.  
2.10. HPLC Analysis 
The stability samples of prodrugs and their metabolites, and perfusion samples were determined on 
an Agilent HPLC system (Agilent Technologies, Santa Clara, CA, USA). The HPLC system consisted 
of Agilent pumps (1100 series), an Agilent autosampler (1200 series), and an Agilent UV-Vis detector 
(1100 series) controlled by Chemstation® 32 software (version B.01.03). Samples were resolved in an 
Agilent Eclipse Plus C18 reverse-phase column (3.5 µm, 4.6 × 75 mm) equipped with a guard column. 
The mobile phase consisted of 0.1% TFA/water (Solvent A) and 0.1% TFA/acetonitrile (Solvent B) 
with the solvent B gradient changing from 0%–56% at a rate of 2%/min during a 15 min run for 
gemcitabine and gemcitabine prodrugs. Standard curves generated for each prodrug and their parent 
drug were utilized for quantitation of integrated area under peaks. The detection wavelength was 254 nm 
and spectra were acquired in the 220–380 nm wavelength range. The detection wavelength for phenol 
red was 430 nm. 
  
C'out
C'in =
Cout
Cin ×
Cin phonol red
Cout phenol red 
ܲeff =
−Q ln ቀC′outC′in ቁ
2πRL  
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2.11. LC-MS Analysis 
The LC-MS analytical method of 5′-mono amino acid ester prodrugs of floxuridine has been 
reported previously [50]. The LC-MS analysis of dipeptide monoester prodrugs of floxuridine and 
gemcitabine along with their parent drugs was modified and performed in a similar manner. Briefly, 
LC-MS analysis of the uptake drug amount was performed in triplicate on LCMS-2010EV (Shimadzu 
Scientific Instruments, Kyoto, Japan) equipped with an ESI (electrospray ionization) source.  
The Shimadzu LC-MS system consisting of Shimadzu LC-20AD pumps with DGU-20A in-line 
vacuum degasser units, and SIL-20A HT autosampler with an InertSustain C-18, 2.1 × 50 mm, 3 µm 
particle size, (GL Sciences, Torrance, CA, USA) was used for the separation and the effluent from the 
column was introduced directly to the ionization source. The system was controlled by Shimadzu 
LCMS solution software (version 3) to collect and process data. All samples were run with Solvent A 
and Solvent B with Solvent B gradient changing from 0%–90% at a rate of 13.8%/min over a 22 min 
run. The mobile phase consisted of 0.1% TFA/water (Solvent A) and 0.1% TFA/acetonitrile (Solvent B) 
for gemcitabine, gemcitabine prodrug and floxuridine prodrug. The mobile phase consisted of 0.1% 
ammonium hydroxide/water (Solvent A) and 0.1% ammonium hydroxide /acetonitrile (Solvent B) for 
floxuridine. The ESI probe was operated with a detector voltage of 1.5 kV, CDL temperature of 250 °C, 
heat block of 200 °C, and nebulizing gas flow of 1.2 mL/min in positive mode for gemcitabine 
prodrugs and their metabolites. The drying gas was N2 delivered at 0.1 MPa. 
2.12. Statistical Analysis 
Statistical analysis was performed by Student’s t-test for two groups. All results were  
expressed as the mean ± standard deviation (SD). A probability (p) of less than 0.05 is considered  
statistically significant. 
3. Results and Discussion 
3.1. Floxuridine and Gemcitabine Prodrugs 
The syntheses of the prodrugs and their characterization have been described in the previous  
report [7,11–13]. The structures and analytical data of those prodrugs were shown in Figure 1 and Table 1. 
Figure 1. Dipeptide monoester prodrugs of floxuridine and gemcitabine. 
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Table 1. Analytical data for dipeptide ester prodrugs of floxuridine and gemcitabine. 
Prodrug 
Purity (%) 
(HPLC) 
ESI-MS (M+H)+ 
LogP a 
Required Observed 
Gemcitabine 95.3 263.2 263.9 −1.14 
5′-L-Phenylalanyl-L-tyrosylgemcitabine 95.5 b 574.5 574.4 1.04 
Floxuridine 100.0 246.2 245.0 −0.51 
5′-L-Phenylalanyl-L-tyrosyl-floxuridine 99.0 557.2 557.2 0.12 
a Calculated using BioLoom; b Mixture of 5′-L-phenylalanyl-L-tyrosylgemcitabine and its diastereomer. 
3.2. The Stability of Floxuridine, 5′-L-Phenylalanyl-L-Tyrosyl-floxuridine, Gemcitabine, and  
5′-L-Phenylalanyl-L-Tyrosyl-gemcitabine in Three Buffers (Acidic pH, SIF (pH 6.0), and pH 7.4), and 
Caco-2, Panc-1, and AsPC-1 Cell Homogenates 
The experiments concerning drug and their prodrug stability were performed at 37 °C in 0.01 N 
HCl, SIF (pH 6.0), and pH 7.4 phosphate buffer. The estimated half-lives (t1/2) obtained from linear 
regression of pseudo-first-order plots of prodrug concentration vs. time for floxuridine,  
5′-L-phenylalanyl-L-tyrosyl-floxuridine, gemcitabine, and 5′-L-phenylalanyl-L-tyrosyl-gemcitabine in 
0.01 N HCl alone, SIF (pH 6.0), pH 7.4 phosphate buffer alone, and in Caco-2, Panc-1, and AsPC-1 
cell homogenates are listed in Table 2. Prodrug metabolites such as floxuridine, 5-fluorouracil (5-FU), 
gemcitabine, 2′-deoxy-2′,2′-difluorouridine, uracil, and cytosine were monitored along with prodrug 
disappearance in this experiment. However, the mass balance could not be established because 5-FU, 
cytosine and uracil were metabolized even further and those metabolites could not be quantified by 
HPLC [11,50]. The specific kinetic parameters in drug/prodrug metabolism could not be determined 
without the mass balance and the data of enzymatic activities and their expression levels because those 
metabolic activities were simultaneously taken place. All tested drugs including dipeptide prodrugs 
showed the good chemical stability except 5′-L-phenylalanyl-L-tyrosyl-gemcitabine in 0.01N HCl, 
SIF, and pH 7.4 phosphate buffer. Gemcitabine was more chemically and enzymatically stable than 
another nucleoside analog, floxuridine (Table 2). 5′-L-Phenylalanyl-L-tyrosyl-floxuridine exhibited the 
best stability among tested compounds even though its parent drug, floxuridine, showed less stability 
compared to the other parent drug, gemcitabine. Gemcitabine prodrug exhibited 3.9- to 7.1-fold shorter 
half-lives in cell homogenates than its parent drug, gemcitabine, while floxuridine prodrug exhibited 
7.3- to 9.3- fold longer half-lives in cell homogenates than its parent drug, floxuridine. The stability of 
5′-L-phenylalanyl-L-tyrosyl-floxuridine was 1.3- and 7.4-fold better enzymatically in cell homogenates 
than one of 5′-L-phenylalanyl-L-tyrosyl-gemcitabine, while the stability of its parent drug, floxuridine, 
was 2.9- and 7.3-fold less enzymatically in cell homogenates than one of gemcitabine. The stability 
profiles of 5′-L-phenylalanyl-L-tyrosyl-gemcitabine in cell homogenates, Caco-2 cells, surrogate for 
intestine, Panc-1 and AsPC-1, surrogate for tumors, suggest that bioconversion of 5′-L-phenylalanyl-L-
tyrosyl-gemcitabine to the parent drug would be much faster than metabolism of its parent drug, 
gemcitabine. The enzymatic stability of 5′-L-phenylalanyl-L-tyrosyl-floxuridine was significantly 
enhanced compared to one of floxuridine suggesting that the 5′ position of dipeptide has the catalytic 
role for its metabolic cascade for floxuridine and the cleavage of the ester bond is the rate-limiting step 
in the metabolic pathway of floxuridine prodrug. 
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Table 2. Stability of floxuridine, floxuridine prodrug, gemcitabine and gemcitabine prodrugs 
in 0.01N HCl, SIF (pH 6.0), pH 7.4 Buffer and biological media (mean ± SD, n = 3). 
Prodrug 
0.01 N 
HCl  
t1/2 (min) 
SIF pH 6.0 
t1/2 (min) 
Buffer pH 7.4 
t1/2 (min) 
Caco-2 cell 
homogenates 
t1/2 (min) 
Panc-1 cell 
homogenates 
t1/2 (min) 
AsPC-1 cell 
homogenates 
t1/2 (min) 
Gemcitabine >120 >120 >120 105.0 ± 6.1 >120 33.7 ± 14.5 
5′-L-Phenylalanyl-L-
tyrosyl-gemcitabine 
>120 >120 33.6 ± 1.4 14.7 ± 4.4 30.2 ± 1.1 8.1 ± 0.6 
Floxuridine >120 >120 >120 14.3 ± 7.0 a 41.7 ± 6.8 6.4 ± 3.2 a 
5′-L-Phenylalanyl-L-
tyrosyl-floxuridine 
>120 >120 >120 103.8 ± 55.5 b 40.4 ± 0.2 59.7 ± 1.4 b 
a Reference [51]; b Reference [11]. 
3.3. Uptake Study of Floxuridine, 5′-L-Phenylalanyl-L-Tyrosyl-floxuridine, Gemcitabine, and  
5′-L-Phenylalanyl-L-Tyrosyl-gemcitabine in Caco-2, Panc-1, and AsPC-1 Cells with Both the Presence 
and the Absence of 10 mM Gly-Pro 
The uptake of dipeptide monoester prodrugs of floxuridine and gemcitabine and their parents, 
floxuridine and gemcitabine, was determined with both the presence and the absence of 10 mM  
Gly-Pro at 37 °C in Caco-2, Panc-1, and AsPC-1 cells. Figure 2 and Table 3 show the uptake amounts 
with observed compound species and the uptake difference with both the presence and the absence of 
10 mM Gly-Pro in Caco-2 cell system. Figure 3 and Table 3 and Figure 4 and Table 3 show the uptake 
amounts with observed compound species in Panc-1 and AsPC-1, ductal pancreatic cancer cell lines, 
cell systems, respectively. Dipeptide prodrugs of floxuridine and gemcitabine exhibited 2.4- to  
48.7-fold higher uptake amount than their parents, floxuridine and gemcitabine in Caco-2, Panc-1,  
and AsPC-1 cells. The uptake amount of floxuridine was not observed in Panc-1 cells, while the one of  
5′-L-phenylalanyl-L-tyrosyl-floxuridine exhibited 48.7 µM/mg of protein in the same cell system.  
5′-L-Phenylalanyl-L-tyrosyl-gemcitabine exhibited 2.4-fold better uptake in Panc-1 cell than their parent, 
gemcitabine (Figure 3). 5′-L-Phenylalanyl-L-tyrosyl-floxuridine and 5′-L-phenylalanyl-L-tyrosyl-
gemcitabine exhibited 11.2- and 8.0-fold better uptakes than their parents in AsPC-1 cell, which 
reportedly overexpress PEPT1 transporter [35]. However, those uptake amounts of dipeptide prodrugs 
and parents did not show meaningful difference between the presence and the absence of Gly-Pro even 
though the dipeptide promoiety, 5′-L-phenylalanyl-L-tyrosine, exhibited the affinity to the PEPT1 
transporter to inhibit glycylsarcosine (Gly-Sar) uptake [11]. Those results suggest that the improved 
cellular uptake of prodrugs in those cell lines was attributed not only to the carrier mediated processes 
but also to increased passive processes by prodrug design. The uptake amounts of dipeptide prodrugs 
were significantly lower in AsPC-1 cells compared to their corresponding values in Caco-2 and Panc-1 
cells. Gemcitabine was degraded almost three- to four- times faster in AsPC-1 cells than in Caco-2 and 
Panc-1 cells, while floxuridine was degraded two- to six-times faster in AsPC-1 cells than in those 
cells. Those indicate that prodrug stability and enzyme upregulation in AsPC-1 cells would be largely 
attributed to the observed uptake amount for floxuridine and gemcitabine prodrugs and their 
metabolites. Those uptake results exhibited different pattern of drug species in those three cell lines 
suggesting the different rates for membrane permeability, enzymatic activation and metabolism.  
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The uptake of dipeptide prodrugs in Caco-2 cell exhibited 6%–45% of prodrug form, 47%–91% of 
parent drug form and 3%–8% of metabolite, 5-FU and cytosine, while the uptake of dipeptide prodrugs 
in Panc-1 cell exhibited 9%–98% of prodrug form, 2%–15% of parent drug form and 0%–76% of 
metabolite (Table 3). In AsPC-1 cell, the uptake of dipeptide prodrugs in AsPC-1 cell exhibited 39%–60% 
of prodrug form, 0%–33% of parent drug form and 28%–40% of metabolite (Table 3). Those results 
suggested that dipeptide floxuridine prodrug is more stable than dipeptide gemcitabine prodrug even 
though the promoiety for those prodrugs is the same. However, floxuridine, its parent drug, was less 
stable than gemcitabine. When the floxuridine prodrug was metabolized to floxuridine, floxuridine was 
quickly metabolized to 5-FU by enzymes like thymidine phosphorylase and, therefore, only 0%–47% 
of floxuridine was observed compared to 15%–91% of gemcitabine in those uptake studies (Table 3). 
Those results suggest that the expression level of metabolizing enzymes in those cells for prodrugs and 
their parents was different. As a result, the bioactivation rates for those prodrugs and parents were different. 
Figure 2. The uptake study with floxuridine, 5′-L-phenylalanyl-L-tyrosyl-floxuridine, 
gemcitabine, and 5′-L-phenylalanyl-L-tyrosyl-gemcitabine found in Caco-2 cells with 1 h 
incubation with both the presence and the absence of 10 mM Gly-Pro. Each column 
represents total amount of floxuridine/gemcitabine prodrug, floxuridine/gemcitabine, and 
5-FU/cytosine. Data are expressed as the amount, µM/mg of protein, mean ± SD, n = 3.  
* p < 0.05, the uptake amount of dipeptide prodrugs is compared with their parents, 
floxuridine and gemcitabine. 
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Table 3. Composition of floxuridine, floxuridine prodrug, gemcitabine and gemcitabine 
prodrug in Caco-2, Panc-1, and AsPC-1 cell uptake studies (mean ± SD, n = 3). 
Compound Cells Metabolite * (%) Parent drug * (%) 
Prodrug
(%) 
Gemcitabine 
Caco-2 
5 95 - 
5′-L-Phenylalanyl-L-tyrosyl-gemcitabine 3 91 6 
Floxuridine 100 0 - 
5′-L-Phenylalanyl-L-tyrosyl-floxuridine 8 47 45 
Gemcitabine 
Panc-1 
80 20 - 
5′-L-Phenylalanyl-L-tyrosyl-gemcitabine 76 15 9 
Floxuridine 0 0 - 
5′-L-Phenylalanyl-L-tyrosyl-floxuridine 0 2 98 
Gemcitabine 
AsPC-1
10 90 - 
5′-L-Phenylalanyl-L-tyrosyl-gemcitabine 28 33 39 
Floxuridine 67 33 - 
5′-L-Phenylalanyl-L-tyrosyl-floxuridine 40 0 60 
* Metabolite and parent drug are referred to cytosine and gemcitabine for a gemcitabine prodrug and to 5-FU 
and floxuridine for a floxuridine prodrug, respectively. 
Figure 3. The uptake study with floxuridine, 5′-L-phenylalanyl-L-tyrosyl-floxuridine, 
gemcitabine, and 5′-L-phenylalanyl-L-tyrosyl-gemcitabine found in Panc-1 cells with 1 h 
incubation with the presence and the absence of 10 mM Gly-Pro. Each column represents 
the total amount of floxuridine/gemcitabine prodrug, floxuridine/gemcitabine, and  
5-FU/cytosine. Data are expressed as the amount, µM/mg of protein, mean ± SD, n = 3.  
* p < 0.05, the uptake amount of dipeptide prodrugs is compared with their parents, 
floxuridine and gemcitabine. 
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Figure 4. The uptake study with floxuridine, 5′-L-phenylalanyl-L-tyrosyl-floxuridine, 
gemcitabine, and 5′-L-phenylalanyl-L-tyrosyl-gemcitabine found in AsPC-1 cells with 1 h 
incubation with the presence and the absence of 10 mM Gly-Pro. Each column represents 
the total amount of gemcitabine prodrug, gemcitabine, and cytosine. Data are expressed as 
the amount, µM/mg of protein, mean ± SD, n = 3. * p < 0.05, the uptake amount of 
dipeptide prodrugs is compared with their parents, floxuridine and gemcitabine. 
 
3.4. In Situ Permeability of Floxuridine, 5′-L-Phenylalanyl-L-Tyrosylfloxuridine, Gemcitabine, and  
5′-L-Phenylalanyl-L-Tyrosylgemcitabine in the Single-Pass Intestinal Perfusion Study and the Drug 
Concentration in Plasma in Mice 
The effective permeability (Peff) values obtained for floxuridine, 5′-L-phenylalanyl-L-tyrosyl-
floxuridine, gemcitabine, and L-phenylalanyl-L-tyrosylgemcitabine in small intestinal segments in 
mice at physiological pH are presented in Table 4. The in situ permeability of parent drugs, floxuridine 
and gemcitabine, exhibited 0.1 × 10−5 cm/s and 0.2 × 10−5 cm/s in the mouse jejunum, respectively.  
On the other hand, the in situ permeability of dipeptide monoester prodrugs of floxuridine and 
gemcitabine exhibited 19.0- to 11.0-fold higher membrane permeability than their parent drugs (Table 4).  
The gemcitabine prodrug exhibited superior membrane permeability to the floxuridine prodrug.  
5′-L-phenylalanyl-L-tyrosylfloxuridine displayed the highest drug concentration in mouse plasma after 
in situ perfusion and dipeptide prodrugs exhibited 53.0- and 5.5-fold higher drug concentration in 
mouse plasma than their parents, respectively. The majority (81%) of totally observed amount of a 
floxuridine prodrug in the systemic circulation was 5′-L-phenylalanyl-L-tyrosylfloxuridine after in situ 
perfusion study in mice, while only 40% of totally observed amount of a gemcitabine prodrug was  
5′-L-phenylalanyl-L-tyrosylgemcitabine (Figure 5). Interestingly, 5-FU, the first metabolite of 
floxuridine, from 5′-L-phenylalanyl-L-tyrosylfloxuridine was not observed, while cytosine, the first 
metabolite of gemcitabine, from 5′-L-phenylalanyl-L-tyrosyl-gemcitabine was detected and exhibited 
one-third of totally observed amount. For parent drugs, floxuridine and gemcitabine, the majority 
(83%) of totally observed amount was gemcitabine, while floxuridine was only drug observed in mouse 
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plasma after in situ perfusion. Those results suggested that the faster metabolism of floxuridine and  
5-FU compared to gemcitabine and cytosine and agreed with in vitro stability studies in cell 
homogenates (Table 2). The effective permeability (Peff) values of dipeptide prodrugs as well as their 
parent drugs in mouse jejunal intestine are consistent with the trends observed in uptake studies in 
Caco-2 cells. The excellent correlation between the uptake amount in Caco-2 cells and the drug 
concentration in mouse plasma after in situ perfusion was observed even though sample points were 
limited (R2 = 0.99), which agreed with our previous findings (Figure 6) [52]. 
Table 4. Effective (Peff) permeability coefficients of floxuridine, floxuridine prodrug, 
gemcitabine and gemcitabine prodrug in in situ perfusion study in mouse (mean ± SD, n = 3). 
Prodrug/drug Peff, mouse perfusion (×10−5 cm/s) 
Gemcitabine 0.2 ± 0.2 
5′-L-Phenylalanyl-L-tyrosyl-gemcitabine 2.2 ± 0.4 * 
Floxuridine 0.1 ± 0.8 
5′-L-Phenylalanyl-L-tyrosyl-floxuridine 1.9 ± 0.1 * 
* p < 0.05, the permeability of dipeptide prodrugs is compared with their parents. 
Figure 5. The concentration of floxuridine, floxuridine prodrug, gemcitabine and gemcitabine 
prodrug found in plasma at 2 h following in situ single-pass intestinal perfusion to the 
mouse jejunum. Each column represents prodrug, its parent drug, and its metabolite. Data 
are expressed as the concentration, ng/mL, mean ± SD, n = 3. Error bars are shown for the 
total concentration. * p < 0.05, the uptake amount of dipeptide prodrugs is compared with 
their parents, floxuridine and gemcitabine. 
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Figure 6. The correlation between the drug concentration in mouse plasma after in situ 
perfusion and the uptake amount of dipeptide prodrugs and their parents, floxuridine and 
gemcitabine, in Caco-2 cells. Values are the mean ± SD, n = 3. 
 
3.5. Cell Proliferation Assay 
GI50 values for floxuridine, 5′-L-phenylalanyl-L-tyrosylfloxuridine, gemcitabine, and 5′-L-phenyl-
alanyl-L-tyrosylgemcitabine, determined in cell proliferation studies with the pancreatic ductal cell 
lines, AsPC-1 and Panc-1, are shown in Table 5. Dipeptide prodrugs exhibited 2.0- to 2.7-fold enhanced 
anti-proliferative activity in AsPC-1 cell compared to their parents, floxuridine and gemcitabine. The 
parent drugs did not show any anti-proliferative activity in Panc-1 cell within the tested drug 
concentrations, while dipeptide prodrugs of those parent drugs exhibited around 3 mM of GI50 values 
(Table 5). The cell proliferation studies in the pancreatic ductal cancer cell lines confirmed the 
enhanced potency of the dipeptide monoester prodrugs compared to parents, floxuridine  
and gemcitabine. The results of uptake study in AsPC-1 and Panc-1 cells suggested that the enhanced 
anti-proliferative effect on cancer cells attributed the improved membrane permeability of a 
floxuridine prodrug and a gemcitabine prodrug regardless of carrier-mediated transporters. The GI50 
values of prodrugs did not exhibit any discernible correlations with their uptake values in AsPC-1 and 
Panc-1 cells. Since the bioconversion rates of prodrugs and the metabolic rates of prodrugs and their 
parent drugs will be various, the time of transported drugs/prodrugs into cancer cells and of activated 
prodrugs to reach their maximum anti-proliferation activity will be different [47]. Therefore, to 
distinguish a significant correlation between GI50 values and prodrug/drug permeabilities with a 
limited experimental time course would be extremely difficult. 
Despite this improvement of modified nucleoside analogs in membrane permeability and  
anti-proliferative activity, the delivery of those chemotherapeutic agents to the systemic circulation 
would not be enough to reach the same level of drug concentration obtained by intravenous 
administration, which steadily distributes higher drug concentration in the systemic circulation. 
However, this less exposure of chemotherapeutic agent might be the better way to treat cancers. 
Maximum tolerated dose (MTD) of chemotherapeutic agents has been clinically used to treat various 
cancer patients with multiple short therapeutic regimens, which generally require prolonged breaks 
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from this type of therapies because of toxic side effects. Instead of the treatment with MTD of 
chemotherapeutic agents, the treatments with low and more frequent doses of chemotherapeutic agents 
called metronomic chemotherapy have been praised for its better antitumor effects and less  
toxicity [53–58]. With this metronomic approach, the development of orally administrable cancer 
drugs might be more feasible and beneficial for cancer patients. Indeed, the pre-clinical and clinical 
studies including metronomic therapy with other gemcitabine derivatives such as SL-01, CP-4126 and 
LY2334737, which are orally administrable gemcitabine prodrugs, have been conducted and have 
demonstrated therapeutic benefits of those prodrugs over their parent, gemcitabine [59–66]. CP-4126 
and 5′-L-phenylanalyl-L-tyrosyl-gemcitabine contain a fatty acid chain and a dipeptide at their 5′ 
position, respectively, while nothing is bound to LY2334737 and SL-01 at their 5′ position. Most of 
chemotherapeutic agents like gemcitabine are DNA-damaging agents to inhibit or even kill rapidly 
dividing cells. Gemcitabine is generally administered intravenously in the clinic weekly basis and 
incorporated into DNA to apoptosis [64,67–70]. Gemcitabine and its prodrugs, SL-01 and LY2334737, 
can be phosphorylated and incorporated into DNA without any molecular modification because of free 
5′ position. On the other hand, the promoiety of gemcitabine prodrugs, dipeptide prodrugs and  
CP-4126, at 5′ position has to be cleaved and phosphorylated before incorporated into DNA. This 
metabolic process could be an advantage to improve the tumor selectivity and targetability when, 
especially, tumor-related enzymes in tumor cells specifically metabolize a prodrug to release its parent 
drug. Indeed, prodrugs have been designed to be activated by enzymes that are specifically expressed 
in tumor in order to improve the tumor selectivity and, hence, to minimize the toxic effect at  
non-tumor sites [46,71–77]. The dipeptide prodrugs of floxuridine, 5′-L-phenylanalyl-L-tyrosyl-floxuridine, 
as well as gemcitabine, 5′-L-phenylanalyl-L-tyrosylgemcitabine, might be favorably activated by the 
enzyme which is highly up-regulated in the tumor cells [47]. 
Nucleoside transporters are believed to be responsible transporting nucleoside analogs like 
gemcitabine into cancer cells [78,79]. Delivery of gemcitabine into tumor cells relies on intake 
transporters such as nucleoside transporters (ENTs). However, the cancer treatment with nucleoside 
analogs like gemcitabine leads to down-regulation of ENTs and up-regulation of efflux transporters, 
multidrug resistance proteins (MRPs), in tumor cells and, as a result, those tumors exhibit the 
chemoresistance against chemotherapeutic medications [80–83]. In some cancers, up-regulation or 
high expression of nutrient transporters has been reported but down-regulation of those has not been 
reported [35,84–86]. Therefore, amino acid and dipeptide prodrugs of chemotherapeutic agents might 
have another advantage transporting drugs into cancer cells via influx transporters such as LATs, and 
PEPTs except ENTs [7,11,16,87]. It has been reported that the chemoresistance is attributed to the  
up-regulation of MRPs, especially MRP5 [80,81,88–90]. Numerous studies have been conducted  
to overcome this resistance to treat cancers but clinically successful approaches have not been 
established [91–95]. Systemic chemotherapy has significantly improved the therapeutic index in 
cancers but the development of drug resistance limits the chemotherapeutic efficacy and  
further improvement. The drug resistance in chemotherapy is developed in very complex process  
and the mechanism of this chemotherapeutic resistance should be studies and understood for better 
cancer treatment. 
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Table 5. Cell Growth Inhibition in AsPC-1 and Panc-1 Cells by floxuridine, floxuridine 
prodrug, gemcitabine, and gemcitabine prodrug (mean ± SD, n = 3–5). 
Prodrug/drug GI50 AsPC-1 (mM) GI50 Panc-1 (mM) 
Gemcitabine 10.2 ± 1.6 ND 
5′-L-Phenylalanyl-L-tyrosyl-gemcitabine 5.0 ± 0.3 3.2 ± 0.7 
Floxuridine 22.9 ± 5.7 # ND 
5′-L-Phenylalanyl-L-tyrosyl-floxuridine 4.2 ± 0.1 3.0 ± 0.3 
ND-no significant inhibitory effect was observed. # Ref. [11]. 
4. Conclusions 
The observed species of floxuridine prodrugs and gemcitabine prodrugs in cellular uptake studies 
may illustrate that transported drugs are converted to floxuridine and 5-FU and to gemcitabine and 
cytosine via a sequential enzymatic pathway, respectively [11,50]. The dipeptide prodrugs of 
nucleoside analogs, floxuridine and gemcitabine, demonstrated the superior membrane permeability to 
their parent drugs. As a result, those prodrugs exhibited higher concentration of cancer drugs in 
pancreatic cancer cells, AsPC-1 and Panc-1, and better anti-proliferative activity. Our results indicate 
that dipeptide monoester prodrugs of floxuridine and gemcitabine exhibit significantly higher 
permeability in mouse intestinal membrane than their parent drugs, floxuridine and gemcitabine, which 
agreed with our previous findings in the membrane permeability across Caco-2 monolayers [11].  
Also, uptake amounts of those prodrugs exhibited more in three different cells than ones of their  
parent drugs. Dipeptide gemcitabine prodrug, 5′-L-phenylanalyl-L-tyrosylgemcitabine, displayed 
significantly higher permeability in mouse intestinal membrane but the other dipeptide prodrug,  
5′-L-phenylanalyl-L-tyrosyl-floxuridine exhibited the highest prodrug concentration in blood with 
slightly better anti-proliferative activity against pancreatic ductal cancer cells, Panc1 and AsPC-1. 
Both prodrugs clearly exhibited superior membrane permeability and, hence, anti-proliferative 
activities to their parents. With the difference in enzymatic stability between prodrug and parent drug, 
the 5′-L-phenylanalyl-L-tyrosylfloxuridine has an advantage in prodrug delivery into the systemic 
circulation over 5′-L-phenylanalyl-L-tyrosylgemcitabine. However, its metabolite, floxuridine, is 
quickly metabolized further in the systemic circulation. On the other hand, gemcitabine displayed 
more enzymatic stability in the systemic circulation and might have more advantage over floxuridine 
as an orally administrable chemotherapeutic agent. This question might be addressed by 
pharmacokinetics studies. Taken together, the dipeptide prodrugs of nucleoside analogs exhibited 
enhanced membrane permeability, the higher prodrug concentration in plasma after in situ perfusion, 
and the improved in vitro anti-cancer effect. The improvements would prove the feasibility for the 
development of oral dosage form for pyrimidine analogues. However, the stability and permeability of 
those prodrugs have to be improved more in order to achieve the therapeutic drug concentration to 
inhibit tumor growth in vivo. Current data exhibits that oral prodrug dosage forms cannot simply 
replace the intravenous administration of chemotherapeutic agents. With careful investigation of dose 
optimization, dosage regimen, and combination therapy, those prodrugs might be more suitable for 
metronomic chemotherapy than one for orthodox chemotherapy. Prodrug approaches provide a 
powerful tool to improve physicochemical properties of drug with chemical modification and 
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conjugation for better therapeutic efficacy. The cancer drugs with improved oral bioavailability should 
easily improve the patient compliance and also improve the life flexibility for cancer patients, who 
often have to visit the hospital for their chemotherapeutic regiments because of intravenous treatment. 
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